Cognitive impairment, termed chemobrain, is a common neurotoxicity associated with chemotherapy treatment, affecting an estimated 78% of patients. Prompted by the hypothesis that neuronal mitochondrial dysfunction underlies chemotherapyinduced cognitive impairment (CICI), we explored the efficacy of administering the small-molecule pifithrin (PFT)-m, an inhibitor of mitochondrial p53 accumulation, in preventing CICI. Male C57BL/ 6J mice injected with cisplatin AE PFT-m for two 5-day cycles were assessed for cognitive function using novel object/place recognition and alternation in a Y-maze. Cisplatin impaired performance in the novel object/place recognition and Y-maze tests. PFT-m treatment prevented CICI and associated cisplatin-induced changes in coherency of myelin basic protein fibers in the cingular cortex and loss of doublecortin þ cells in the subventricular zone and hippocampal dentate gyrus. Mechanistically, cisplatin decreased spare respirator capacity of brain synaptosomes and caused abnormal mitochondrial morphology, which was counteracted by PFT-m administration. Notably, increased mitochondrial p53 did not lead to cerebral caspase-3 activation or cytochrome-c release. Furthermore, PFT-m administration did not impair the anticancer efficacy of cisplatin and radiotherapy in tumor-bearing mice. Our results supported the hypothesis that neuronal mitochondrial dysfunction induced by mitochondrial p53 accumulation is an underlying cause of CICI and that PFT-m may offer a tractable therapeutic strategy to limit this common side-effect of many types of chemotherapy.
Introduction
Advances in the efficacy of cancer treatment have led to a sharp increase in the number of cancer survivors, which has reached nearly 15 million in the United States alone (1, 2) . However, in many cases cancer treatment is associated with severe neurotoxic side effects, including fatigue, peripheral pain (3), paresthesia, and cognitive deficits, that can persist long after completion of treatment (4) . These neurotoxicities not only disrupt social, educational, and occupational functioning, but also decrease survival by interfering with adherence to medication and health behavior.
In humans, chemotherapy-induced cognitive impairment (CICI), so-called "chemobrain," is characterized by subtle to moderate cognitive deficits, including a decrease in processing speed, memory, executive functioning, and attention, as assessed by neuropsychological tests (4) (5) (6) . CICI has been noted in 78% of cross-sectional and 69% of prospective longitudinal studies performed between 1995 and 2012 in patients treated for breast cancer (7) (8) (9) . One in two adults is projected to be diagnosed with cancer in his or her lifetime, implying that CICI represents a growing public health concern.
Advanced neuroimaging techniques have revealed that chemotherapy causes structural alterations in white and gray matter in patients with cancer, along with an increased level of activation of the fronto-parietal attentional network (5) . However, little is known about the mechanism underlying CICI, and no preventive or curative interventions have been approved by the FDA.
Platinum-based chemotherapeutic agents like cisplatin are widely used to treat solid tumors (10) . Traditionally, these agents have been thought to act on tumor cells by preferential binding to the guanine residues in DNA to induce crosslinking (11) . The body's subsequent inability to repair damaged DNA leads to an arrest in mitosis, inhibition of cell proliferation, and tumor cell death.
Preclinical studies have shown that cisplatin crosses the bloodbrain barrier and impairs adult neurogenesis in the brain (12) . We recently showed that cisplatin-induced cognitive impairment in mice was associated with increased coherency of white-matter structures and sharp decrease in the number of neuronal dendritic spines and arborizations (2) .
In rodent models, peripheral neuropathy induced by cisplatin or other chemotherapeutic agents such as taxanes is associated with structural damage to mitochondria in the dorsal root ganglia and peripheral nerves (13) . In general, damaged mitochondria can give rise to increased oxidative stress, inflammation, and proapoptotic signaling (14) . We recently showed that co-administration of the small-molecule pifithrin (PFT)-m, an inhibitor of mitochondrial p53 accumulation, protects against taxaneinduced and cisplatin-induced peripheral neuropathy (3) . In addition, we have demonstrated that PFT-m is neuroprotective in a model of neonatal hypoxic-ischemic brain damage by preventing neuronal apoptosis (15) .
In this study, we investigated whether cerebral neuronal mitochondrial damage is the underlying mechanism of cisplatininduced cognitive impairment. Moreover, we tested whether PFT-m is capable of preventing the development of cisplatininduced chemobrain and precluding structural alterations in the brain with respect to damage to white matter and neurogenic areas in the brain.
Materials and Methods

Animals
C57BL/6J male mice were used in this study. Mice were bred inhouse and were allowed water and food ad libitum. Housing was kept constant at 22 AE 2 C, and a 12/12 hours reverse dark-light cycle (dark 1,000-2,200 hours) was employed. Video recording of animal behavior was performed under red light using a Sony Handycam DCR-SR100.
All experiments were conducted at The University of Texas MD Anderson Cancer Center in Houston, Texas. Animal usage was carried out in accordance with Institutional Animal Care and Use Committee-approved protocols.
Injections
Cisplatin (2.3 mg/kg; Fresenius Kabi USA) or PBS was administered intraperitoneally daily for 5 days, followed by a 5-day rest with no injection and then another 5-day injection cycle. To investigate the effects of PFT-m on cognitive function, PFT-m (8 mg/kg; Sigma-Aldrich/Millipore Sigma) or vehicle (5% dimethyl sulfoxide in saline) was administered intraperitoneally 1 hour before cisplatin injection.
Novel object/place recognition and Y-maze tests
To assess cognitive function, we subjected mice to novel object/place recognition (NOPR) and Y-maze tests 7 days after the final cisplatin injection. All behavioral assays were performed in a blinded setup. NOPR was performed as we have previously described (2) . In brief, mice were transferred to a testing arena (46.99 cm Â 25.4 cm) containing two identical objects placed against one side of the arena for 5 minutes (training phase) and then returned to their home cages for 30 minutes. Mice were transferred back to the arena, now containing one familiar object placed at the same location as in training, and one novel object placed on the opposite end of the arena (testing phase). Investigative behavior toward either object during the 5-minute testing period was evaluated using EthoVision XT 10.1 video tracking software (Noldus Information Technology Inc.). Discrimination index was determined by the equation
For the Y-maze test, spontaneous alternations were performed as previously described (16) . In brief, mice were placed in a symmetrical three-arm, gray plastic Y-maze (35 cm length Â 5 cm width Â 15.5 cm height per arm, with an arm angle of 120 ) with external spatial room cues. Mice were randomly placed in one of the arms. Movement was recorded for 5 minutes, and mouse exploration was evaluated. Perfect alternations were defined as exploration of all three arms sequentially before reentering a previously visited arm. All four paws must have been within the arm to be counted as an entrance. Results are represented as the ratio of the number of perfect alternations to the total number of possible alternations.
Locomotion
Spontaneous locomotor activity was measured as described previously (16) (17) (18) (19) (20) . In brief, mice were video recorded for 5 minutes in their home cage. Distance travelled was quantified using EthoVision XT 10.1 (Noldus Information Technology, Inc.).
Body weight
Body weights were measured daily at the time of injection. The percentage of change from baseline (day 0) was calculated.
Tumor response to chemoradiation
We used a heterotopic syngeneic murine model of human papillomavirus (HPV)-related head and neck cancer to assess whether PFT-m might potentially interfere with the tumor's response to chemoradiation (21) (22) (23) . Male C57BL/6J mice were injected in the hind leg with 1 Â 10 6 cells derived from C57BL/6 oropharyngeal epithelial cells that were transfected with oncogenes E6/7 of HPV 16 and hRAS (21, 22) . Mice were injected with PFT-m (8 mg/kg) or vehicle 24 hours before a curative regimen of cisplatin (5.28 mg/kg intraperitoneally; Calbiochem, EMD Millipore) and local irradiation (8 Gy provided by a small-animal cesium 137 irradiator that collimates parallel opposed radiation beams to a 3-cm field) starting 12 days after tumor implantation and repeated weekly for 3 weeks (22) . Tumor volume was determined using Vernier calipers from three mutually orthogonal tumor diameters, where volume ¼ (p/6)(d1Âd2Âd3).
Quantitative real-time polymerase chain reaction
Chemotherapy is thought to induce a low-grade inflammation in patients with cancer that may contribute to neurotoxic side effects, including cognitive dysfunction (24) (25) (26) . We analyzed the effect of cisplatin on the expression of certain prototypic proinflammatory cytokines and glial activation markers in the hippocampus and frontal cortex at the mRNA level. RNA was isolated as described previously (16, 18, 20) . In brief, mice were perfused postmortem with ice-cold PBS, and the hippocampus and prefrontal cortex were dissected from whole brain. RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems/Thermo Fisher Scientific). The Prime-Time qPCR Assays used were IL1b (NM_008361 (1), IL6 (NM_031168(1), TNFa (NM_013693(1), CD11b [Itgam; NM_008401(2)], glial fibrillary acidic protein (GFAP; NM_010277(1), and glyceraldehyde 3-phosphate dehydrogenase [GAPDH; NM_008084(1); Integrated DNA Technologies]. qRT-PCR was performed on a CFX384 Real-Time System (BioRad Laboratories) using TaqMan Universal PCR Master Mix (Applied Biosystems).
Immunohistochemistry
The integrity of the neurogenic stem cell niche is crucial for adequate cognitive function (27, 28) ; we have found that cisplatin reduces white-matter integrity as analyzed at the level of the coherency of myelin basic protein (MBP) fibers in the cingulate cortex (2) . We therefore performed fixation and immunostaining of neuronal precursors in the subventricular zone (SVZ) and dentate gyrus (DG), as previously described (3) . In brief, mice were perfused with 4% paraformaldehyde (PFA). Brains were removed and fixed in 4% PFA for 48 hours, then paraffin embedded and sectioned at 8 mm for the SVZ and cingulum and 10 mm for the DG. Sectioned were stained for doublecortin (DCX, 1:50; Abcam) and MBP (1:100; Abcam). Images were taken at 40Â and 63Â objectives and quantified for positive staining using ImageJ. Cell counting was performed by two experienced and independent researchers blinded to treatment.
Synaptosome isolation
To study whether cisplatin treatment resulted in altered mitochondrial morphology at the time of the behavioral analyses, we prepared synaptosomes of the brains of mice at 7 to 9 days after the last dose of cisplatin. Synaptosomes were isolated according to Kamat and collegues (29) . Briefly, after perfusion with PBS, brains were dissected and homogenized (10% w/v) into a 0. C for 30 minutes at 20,000 Â g. The pellet containing isolated synaptosomes was resuspended in base media (Seahorse Biosciences/Agilent Technologies) supplemented with 11 mmol/L glucose, 2 mmol/L glutamine, and 1 mmol/L pyruvate for oxygen-consumption analysis or 2% glutaraldehyde plus 2% PFA in PBS for transmission electron microscopy.
Transmission electron microscopy
Similar to methods we have previously described (3), synaptosomes were isolated and fixed in a solution containing 2% glutaraldehyde plus 2% PFA in PBS for at least 24 hours. Samples were then fixed with a solution containing 3% glutaraldehyde plus 2% PFA in 0.1 mol/L cacodylate buffer, pH 7.3, then washed in 0.1 mol/L sodium cacodylate buffer and treated with 0.1% Millipore-filtered cacodylate-buffered tannic acid, post-fixed with 1% buffered osmium tetroxide for 30 minutes, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The samples were polymerized in a 60 C oven for approximately 2 days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica Microsystems Inc.), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL USA, Inc.) at an accelerating voltage of 80 kV. Digital images were obtained using AMT Imaging System (Advanced Microscopy Techniques Corp.). Quantifications were performed by two independent researchers using ImageJ.
Oxygen consumption rate
To determine whether the mitochondrial morphologic abnormalities induced by cisplatin treatment and the protective effects of PFT-m were associated with changes in mitochondrial bioenergetics, we analyzed synaptosomal oxygen consumption rates (OCR) using the Seahorse XFe 24 analyzer. Synaptosomes were isolated and plated at 50 mg of total protein on a Seahorse XFe 24 microplate (Seahorse Biosciences) precoated with GelTrex (1 hour in 37 C; Life Technologies/Thermo Fisher Scientific). The plate was centrifuged at 600 Â g for 30 minutes and then allowed to rest at 37 C for 30 minutes. The assay cartridge was loaded with 4 mmol/L oligomycin in Port A, 6 mmol/L carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) in Port B, and 2 mmol/L of rotenone and 2 mmol/L of antimycin A in Port C. The decrease in OCR in response to addition of the complex-III inhibitor oligomycin represents oxygen consumption related to ATP production, whereas the uncoupler FCCP induces maximal OCR. The addition of rotenone/antimycin A inhibits all mitochondrial respiration, leaving only non-mitochondrial oxygen consumption. All values were normalized to mitochondrialdependent respiration.
Mitochondrial isolation
To investigate the mechanism underlying the protective effect of PFT-m, we examined the effect of cisplatin on mitochondrial p53 and on HSP70, a secondary target of PFT-m in proliferating tumor cells (30, 31) . Because it is generally accepted that increases in mitochondrial p53 induce apoptosis through mitochondrial outer membrane permeabilization, leading to activation of caspase-3 and subsequent apoptosis (32), we also examined the effect of cisplatin treatment on brain cytosolic cytochrome-c and activation of caspase-3.
Brains were pulverized using liquid nitrogen-cooled mortar and pestle. Approximately 100 mg of brain sample was homogenized in 700 mL of ice-cold buffer containing 70 mmol/L sucrose, 210 mmol/L mannitol, 5 mmol/L HEPES, 1 mmol/L ethylenediaminetetraacetic acid (EDTA), and protease and phosphatase inhibitors. Homogenates were incubated on ice for 30 minutes, followed by centrifugation at 800 Â g for 10 minutes at 4 C. Collected supernatant 1 was centrifuged at 10,000 Â g for 10 minutes at 4 C to obtain cytoplasmic fraction (supernatant 2) and a mitochondrial pellet.
Mitochondrial protein was obtained by resuspending mitochondrial pellets in ice-cold buffer containing 50 mmol/L Tris, pH 8.0, 1 mmol/L EDTA, 150 mmol/L NaCl, and protease and phosphatase inhibitors, followed by sonication. After incubation on ice for 30 minutes, homogenates were centrifuged at 13,000 Â g for 15 minutes at 4 C, and the supernatant was used as mitochondrial protein. Protein concentration was measured using Bradford assay, according to the manufacturer's instructions.
Western blot analysis
Proteins (35 mg total protein per sample) were separated on 10% SDS-PAGE gel and transferred onto polyvinylidene difluoride membranes (Millipore). Membranes were blocked with 5% nonfat dry milk in 0.1% Tween-PBS (TBST) for 1 hour at room temperature and incubated overnight at 4 C with primary antibodies against p53 (1:500; Cell Signaling Technology, Inc.), HSP70 (1:500; Santa Cruz Biotechnology, Inc.), cytochrome-c oxidoreductase (COX-IV; 1:1,000, Invitrogen/Thermo Fisher Scientific), cleaved caspase-3 (1:1,000, Cell Signaling Technology, Inc.), cytochrome-c (1:1,000, BD Biosciences), Histone H1 (1:800, Abcam), and horseradish peroxidase (HRP)-conjugated mouse anti-b-actin (1:5,000, Sigma-Aldrich) in 5% BSA/TBST. Membranes were washed in TBST and then incubated with HRPconjugated secondary antibodies, either mouse immunoglobulin (Ig)G or rabbit IgG (Jackson ImmunoResearch, West Grove, PA; 1:5,000 in 5% nonfat dry milk/TBST). HRP-conjugated mouse b-actin (Sigma-Aldrich) was incubated for 1 hour at room temperature, washed, and developed. Specific bands were detected with Amersham ECL Western Blotting Detection Reagent (GE Healthcare Bio-Sciences) and captured in the LAS system using Image Quant software for quantification of bands.
Statistical analysis
All data are presented as mean AE SEM. Data were analyzed using GraphPad Prism 6 (GraphPad). One-way or two-way ANOVA was used with or without repeated measure to test for statistical significance where applicable. Post hoc pair-wise, multiple comparisons were performed using the Tukey test when needed. Differences were considered statistically significant at P < 0.05.
Results
Effect of PFT-m on cisplatin-induced cognitive impairment
Cisplatin (2.3 mg/kg) or PBS was administered intraperitoneally daily for 5 days, followed by a 5-day rest period and another 5-day cycle of cisplatin. To investigate the effects of PFT-m on cognitive function, PFT-m (8 mg/kg) or vehicle was administered intraperitoneally 1 hour before cisplatin. The data presented in Fig. 1A and C demonstrate that performance in the NOPR and Y-maze tests was impaired in cisplatin-treated mice, whereas coadministration of PFT-m prevented CICI completely. No differences were observed in the total time the animals interacted with objects in the NOPR, indicating that cisplatin had no effect on interest in the objects or on locomotor activity (Fig. 1B) . Consistently, locomotor activity in the home cage was not affected by cisplatin (Fig. 1D) . PFT-m treatment did not prevent cisplatin-induced loss of body weight (Fig. 1E) . Cisplatin (in the presence or absence of PFT-m) did not induce depressive-like behavior in comparison with PBS-treated animals, as analyzed by sucrose preference (saline: 88.1 AE 1.4%; cisplatin: 90.9 AE 1.3%) and forced-swim tests (saline: 55.2 AE 8.4 seconds; cisplatin: 50.7 AE 11.9 seconds).
Effect of cisplatin and PFT-m on neuronal precursors in the brain
The results in Fig. 2 show that our regimen of cisplatin treatment led to a decrease in the number of DCX þ neural progenitors in the two major neurogenic niches in the brain. After 2 cycles of cisplatin, the number of DCX þ neuroblasts in the DG of the hippocampus decreased by 70% ( Fig. 2A-E) . The number of DCX þ cells in the SVZ decreased by 30% (Fig. 2F-I ). Preventive treatment with PFT-m completely prevented the loss of DCX þ neuroblasts in both the DG and SVZ ( Fig. 2D and I) .
Effect of PFT-m on cisplatin-induced changes in white-matter integrity As shown in Fig. 3A -E, the two 5-day cycles of cisplatin used in the current study increased white-matter coherency, suggesting a loss of arborization and lateral fibers. The latter assumption is supported by the skeletonized MBP þ structures shown in Fig. 3A -
Coadministration of PFT-m prevented the cisplatin-induced increase in white-matter coherency in the cingulate cortex ( Fig. 3D  and D 0 ), implying that PFT-m protects against structural whitematter damage induced by cisplatin.
Effect of cisplatin on the inflammatory response in the brain
In our analysis of the effect of cisplatin on the expression of IL1b, IL6, and TNFa, GFAP, and CD11b, we did not detect any significant increase in cytokine mRNA after cisplatin treatment, as measured 24 hours after the first injection or after the behavioral testing 1 week after the last dose of cisplatin (Table 1) . Taken together, these data indicate that CICI in our mouse model is not associated with typical (neuro)inflammation.
Early effects of cisplatin and PFT-m on p53 translocation to mitochondria and caspase-3 activation Figure 4A shows that the protein level of p53 in isolated brain mitochondrial fractions was increased at 4 and 24 hours after a single dose of cisplatin, as determined by Western blotting. Coadministration of PFT-m completely prevented this cisplatininduced increase in brain mitochondrial p53 (Fig. 4B) . Cisplatin treatment did not lead to an increase in brain cytosolic cytochrome-c or to activation of caspase-3 (Fig. 4C) . The results in Fig. 4D   Figure 1 . Effect of PFT-m on cisplatin-induced cognitive impairment. Animals were treated with cisplatin and PFT-m for two 5-day cycles. A, NOPR was performed 7 days after the last injection, and discrimination index was calculated. B, Total investigation time between both objects in the NOPR was recorded. Results are expressed as means AE SEM; n ¼ 8. *, P < 0.05. C, Y-maze was performed 7 days after the last injection, and percentage of perfect alternation was calculated. Results are expressed as means AE SEM; n ¼ 4. *, P < 0.05. D, Spontaneous locomotor activity (total distance traveled) was measured. Results are expressed as means AE SEM; n ¼ 8. E, The percentage of baseline body weight was recorded. Results are expressed as means AE SEM; n ¼ 12; Ã , P < 0.05 saline/ PBS versus saline/cisplatin; $, P < 0.05 PFT-m/PBS versus PFT-m/cisplatin. confirm the purity of the subcellular fractions and show that there was no effect of cisplatin on cytosolic/nuclear p53. We did not detect changes in brain HSP70 after cisplatin treatment (Fig. 4E) .
Effects of cisplatin and PFT-m on mitochondrial morphology and mitochondrial function
The results in Fig. 5A -F demonstrate that synaptosomal mitochondria of brains of cisplatin-treated animals were swollen and had abnormal cristae when compared with synaptosomal mitochondria from PBS-treated control mice. PFT-m coadministration prevented this long-lasting abnormal morphology of the mitochondria induced by two cycles of cisplatin (Fig. 5D-F) .
Basal respiration of the synaptosomes was not affected by cisplatin (Fig. 5G) , and there was no effect of cisplatin on the oxygen consumption related to ATP production (Fig. 5H) . However, the maximal respiration as determined after addition of the mitochondrial uncoupler FCCP was significantly lower in synaptosomal fractions of cisplatin-treated mice versus PBS-treated control mice (Fig. 5I) . Consequently, the difference between maximal and basal respiration, also known as spare respiratory capacity, was decreased in the synaptosomes from cisplatin-treated mice (Fig. 5J) . Coadministration of PFT-m prevented the cisplatin-induced impairment in maximal and spare respiratory capacity (Fig. 5G-J) . No differences in proton leak between cisplatin-treated and PBS-treated mice were observed (saline: 0.28 AE 0.01 pmol O 2 /mg of protein; cisplatin 0.33 AE 0.11 pmol O 2 /mg of protein). We did not detect cisplatin-induced changes in lipid peroxidation as quantified using a TBARS assay (saline: 4.32 AE 0.24 nmol/L/mg total protein; cisplatin: 4.39 AE 0.38 nmol/ L/mg total protein).
Effect of PFT-m on the sensitivity of the tumor to chemoradiation
We used a heterotopic syngeneic murine model of HPV-related head and neck cancer to assess whether PFT-m might potentially interfere with the tumor's response to chemoradiation (cisplatin þ radiation, CRT). CRT inhibited tumor growth as expected (Fig. 6A) . The response to CRT was not adversely affected by PFT-m treatment. Furthermore, the addition of PFT-m to the cancer treatment did not significantly influence body-weight loss (Fig. 6B ).
Discussion
We show for the first time that the inhibitor of mitochondrial p53 accumulation, PFT-m, prevented cisplatin-induced cognitive impairment or "chemobrain" in mice, as assessed in the NOPR and Y-maze tests (Fig. 1A and C) . The impaired cognitive function observed in cisplatin-treated mice was associated with impaired cerebral neurogenesis (Fig. 2) and structural abnormalities in cerebral white matter that were prevented by PFT-m (Fig. 3) . Mechanistically, we show that cisplatin increased brain mitochondrial p53 levels (Fig. 4) and induced abnormal mitochondrial morphology and impaired the spare respiratory capacity of synaptosomal mitochondria, as shown by Seahorse analysis (Fig. 5) . Notably, PFT-m prevented not only the functional and structural abnormalities induced by cisplatin, but also the cisplatin-induced increase in mitochondrial p53 and the abnormalities in brain mitochondrial function and morphology.
Although (neuro)inflammation has often been proposed as a mechanism for chemotherapy-induced neurotoxicities, we did a not find evidence for increased cytokine production in the brains of cisplatin-treated mice 24 hours or 1 week after the last injection of cisplatin (Table 1 ). In line with these results, we also did not detect microglial or astrocyte activation, as analyzed by Iba-1 and GFAP fluorescence, or a change in the morphological appearance of microglia and astrocytes. Therefore, we suggest that neuroinflammation does not play a major role in CICI. We cannot exclude, however, the possibility of limited region-specific inflammation and/or short-lasting inflammation at other time points. Interestingly, our current data point toward a key role for damage to brain mitochondria as the mechanism underlying CICI. It has been shown that cisplatin-induced peripheral neuropathy is associated with changes in mitochondrial morphology in peripheral sensory neurons (3, 13) . However, to the best of our Figure 4 . Acute effects of cisplatin on p53 translocation to the mitochondria and caspase-3 activation. A and B, Mitochondrial p53 was measured 4 and 24 hours after cisplatin injection (A) and 4 hours after cisplatin and PFT-m injections (B). COX-IV was used as a protein loading control. Relative expression of p53 was calculated 4 and 24 hours after cisplatin treatment. C, The cytosolic fractions were analyzed for the apoptotic markers cytochrome-c and cleaved caspase-3 4, 24, and 72 hours after a single dose of cisplatin. "Con" designates positive controls: brain mitochondria fraction for cytochrome-c (top) and whole-cell lysate of H 2 O 2 -treated N2A cells for active caspase-3 (middle). b-Actin was used as a protein loading control for cytosolic proteins. D, Cisplatin increases mitochondrial p53 without inducing p53 in cytosol or nucleus. Subcellular fractions collected at 4 hours after cisplatin injection were analyzed for p53, Cox-IV (mitochondria), b-actin (cytosol and mitochondria), and Histone H1 (nuclear fraction). E, Cytosolic HSP70. b-actin was used as a protein loading control. Results are expressed as means AE SEM; n ¼ 6; Ã , P < 0.05.
knowledge, we are the first to show that systemic administration of cisplatin induces structural changes in synaptosomal mitochondria ( Fig. 5A-F) . This abnormal morphology is associated with a decrease in mitochondrial bioenergetic function, as reflected by a lower spare respiratory capacity in cerebral synaptosomes of cisplatin-treated mice (Fig. 5G-J) . Spare respiratory capacity is viewed as an index of mitochondrial health and is a measure of how well a cell can produce energy under stressful energy-demanding conditions (13, 33) . Notably, there is evidence that decreased spare respiratory capacity is associated with cognitive impairment in rodent models of Alzheimer disease (34) .
In support of our hypothesis that mitochondrial dysfunction is a central mechanism of CICI, we show here that treatment with PFT-m, which prevents mitochondrial p53 translocation, prevented the reduction in synaptosomal mitochondrial spare respiratory capacity as well as the behavioral deficits, implying a causal relation between mitochondrial protection and CICI. It remains to be determined whether this reduction in spare respiratory capacity in response to cisplatin reflects a general deficit in all mitochondria in the brain or if it is specific for mitochondria in the synapses. The relatively high mitochondrial density in nerve terminals might render this cellular compartment most sensitive to cellular stress (33) . A decrease in mitochondrial function and spare respiratory capacity has also been associated with decreased cognitive ability in Alzheimer's disease (35) and aging (36, 37) . In this respect, it is of interest that advanced neuroimaging has shown that in cancer patients, the severity of cognitive impairment is analogous to multiple years of brain aging (38) .
Strom and colleagues (39) originally identified PFT-m as a compound that inhibits accumulation of p53 at the mitochondria without inhibiting p53 transcriptional activity. These authors showed that PFT-m inhibits radiation-induced p53-dependent thymocyte apoptosis in vitro and in vivo. PFT-m was proposed to protect against apoptosis by reducing the binding of p53 to both Bcl-xL and Bcl-2, resulting in preservation of mitochondrial integrity (39) .
We previously investigated the protective effects of PFT-m in a model of neonatal hypoxic-ischemic (HI) brain damage. PFT-m was shown to prevent HI-induced loss of white and gray matter and to preserve behavioral features like motoric and cognitive function (15) . Mechanistically, HI was shown to increase early neuronal p53 mitochondrial accumulation, reactive oxygen species, and cytosolic accumulation of pro-apoptotic proteins, as measured by increased cytosolic cytochrome-c and activated caspase-3 levels (32) . Here, we show that administration of cisplatin rapidly increased mitochondrial levels of p53, which was prevented by co-administration of PFT-m ( Fig. 4A and B) . However, the increase in mitochondrial p53 as a result of cisplatin treatment did not initiate a general apoptotic cascade, because neither cytosolic cytochrome-c nor activated caspase-3 were increased either at 4 or 24 hours after cisplatin treatment (Fig. 4C) . The absence of apoptosis may have been caused by the fact that cisplatin does not induce early nuclear factor-kB activation and subsequent cytokine synthesis, as was seen early after HI brain damage at the moment of mitochondrial p53 accumulation (32) . However, we did observe structural changes and functional mitochondrial impairment after cisplatin treatment, all of which were prevented by PFT-m (Fig. 5) . Cisplatin treatment did not lead to increases in cytosolic p53. Moreover, as already shown by Strom and colleagues (39) , PFT-m did not interfere with cytosolic p53 levels.
Therefore, we propose that the cisplatin-induced increase in mitochondrial p53 reduces synaptosomal mitochondrial integrity, possibly by decreasing mitochondrial membrane potential (40) , and thereby decreasing the availability of cellular energy under demanding conditions, which may result in oxidative cellular damage in neuronal circuitries engaged in cognition.
At the level of brain structure, we observed cisplatin-induced abnormalities in white-matter structure in the cingulum that were also prevented by PFT-m (Fig. 3) . Moreover, we recently showed that cisplatin reduces arborization and spine density of pyramidal neurons in the cingulum (2) . Van Schependom and colleagues (41) described that neural disconnections, especially of whitematter tracts connecting both hemispheres seen in cognitively impaired versus cognitively preserved patients with multiple sclerosis, were responsible for the cognitive impairment observed in these patients. Diffusion tensor neuroimaging of the brains of lung cancer patients indicates that cisplatin treatment results in an increased fractional anisotropy in areas of white matter in the cingulate cortex. Kesler and colleagues (38, 42) recently published advanced neuroimaging data of patients treated with the anthracycline doxorubicin and concluded that lower memory performance was associated with decreased functional and structural connectivity. In line with these findings, we demonstrate here in mice that cisplatin treatment resulted in increased overall coherency of white-matter fibers in the cingulum, a feature underlying the changes in fractional anisotropy in patients, which may contribute to the observed cognitive impairment. We do not have evidence for an overall decrease in intensity or area of MBP staining, indicating that the major fibers are not lost. Therefore, we conclude that cisplatin treatment leads to a loss of MBP positive branches rather than an overall loss of MBP þ tissue. In a previous study, we showed that cisplatin treatment reduces dendritic branching, as assessed at the individual neuron level using Golgi staining to visualize dendrites (2) . It is likely that the reduction in the complexity of the organization of MBP-staining in the same area is a consequence of the loss of dendritic complexity in response to cisplatin. If so, it is likely that the primary damage is caused by increased p53 binding to neuronal mitochondria, leading to mitochondrial insufficiency, dendritic damage, and subsequent loss of MBP-positive small fibers. However, it is possible that there is a direct effect of cisplatin on mitochondria in oligodendrocytes that could contribute to abnormal patterns of MBP staining in cisplatin-treated mice. For example, it has been shown that cisplatin reduces survival of oligodendrocytes in vitro and in vivo (43) . Therefore, we cannot exclude that in vivo PFT-m prevents the mitochondrial accumulation of p53 in oligodendrocytes as well. Although we do not have evidence for global activation of apoptotic pathways after cisplatin treatment, we cannot exclude that a limited number of cells, such as proliferating cells in the stem cell compartment, undergo apoptotic cell death.
Adult neurogenesis is required for integration of circuitry during learning and memory, as reviewed by Zhao and colleagues (27) , and the sharp decrease in DCX þ cells in the neurogenic niches induced by cisplatin may well contribute to the observed cognitive deficits. Interestingly, the decrease in the number of DCX þ neuroblasts as a result of cisplatin treatment was also completely prevented by PFT-m (Fig. 2) . Preliminary data indicate that the number of uncommitted Nestin þ GFAP þ stem cells in the SVZ did not change under influence of cisplatin, which might indicate that cisplatin selectively affects migrating proliferating neuroblasts (DCX þ ) and/or that the differentiation of uncommitted stem cells to neuroblasts is arrested possibly in favor of glial cells. In this respect, the study of Wang and colleagues (44) , which showed that oxidative damage to mitochondrial DNA in neural stem cells inhibits neural stem cell differentiation and represents a primary signal for elevated astrogliosis, is of interest. Because cisplatin has been shown to damage mtDNA in neurons (45) , the sharp decrease in DCX þ cells may well be a reflection of the relatively high sensitivity of neural stem cells for oxidative damage to mtDNA, in comparison with adult neurons. These data may also imply that the differentiation of the neural progenitors is inhibited in favor of glial differentiation. On the basis of our current data, we propose that mitochondrial protectants may represent an attractive, efficacious treatment for chemotherapy-induced neurotoxicities. It remains to be determined whether the observed reduction in neuronal precursors and the white matter abnormalities are a direct consequence of mitochondrial abnormalities in the synaptosomes or are due to effects of cisplatin on the neuronal stem cells and oligodendrocytes themselves. We recently showed that PFT-m also prevents taxane-induced and cisplatin-induced peripheral neuropathy (3) . Emerging data suggest that PFT-m acts as an anticancer agent (30, (46) (47) (48) . Consistently, we show here in vivo that PFT-m does not interfere with the antitumor efficacy of a cisplatin-based chemoradiation regimen in a heterotopic murine model of HPV-related head and neck cancer. Mechanistically, it has been shown that PFT-m promotes tumor-cell death in vitro and in vivo via an autophagy-promoting mechanism involving interaction with the stress protein HSP70 and lysosome-associated membrane protein 2 in rapidly proliferating tumor cells (30, 31, 46, 48, 49) . These effects of PFT-m on tumor cells are independent of p53.
Taken together, our results indicate that systemic administration of a mitochondrial protectant such as PFT-m may not only be capable of protecting against peripheral and central neurotoxicities, but also will act as an adjuvant therapy to promote tumor cell death without interfering with the efficacy of the cancer therapy. We propose that prevention of mitochondrial p53 accumulation due to chemotherapy is an important therapeutic target to prevent cancer treatment-induced peripheral and central neurotoxicities. The addition of PFT-m to cisplatin may well represent a promising novel therapeutic approach to help fight tumor growth and the development of neurotoxicities in patients with cancer.
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